Floatz logo

Pembrolizumab

Non Seminomatous Germ Cell Tumors

Nasser Hanna, M.D.monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Non Seminomatous Germ Cell Tumors cohort.

Asset / SponsorPhaseRating
Palbociclib
Abramson Cancer Center at Penn Medicine
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
Jennifer King
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
ETOPOSIDE
Nabil Adra
Phase 2CCC

View all 9 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →